Skip to main content
Clinical Trials/NCT01317693
NCT01317693
Unknown
Phase 3

Extracorporeal Shock Wave Therapy With a Wide Focus Probe for the Treatment of Erectile Dysfunction

Rambam Health Care Campus1 site in 1 country70 target enrollmentMarch 2011

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Erectile Dysfunction
Sponsor
Rambam Health Care Campus
Enrollment
70
Locations
1
Primary Endpoint
Change in IIEF-ED Domain Questionaire Score > 5 points is considered treatment success
Last Updated
13 years ago

Overview

Brief Summary

Low intensity shockwaves (1/10 the ones used in Lithotripsy) are delivered to the penile tissue. Shockwaves are created by a special generator and are focused using a specially designed shockwave applicator apparatus. The shockwaves are delivered through the applicator covering the corpora cavernosa of the penis. In previous studies the investigators used a medium focused probe and in this study the investigators are evaluating results of this therapy using a wider focus probe in the aim of improving results of treatment.

Registry
clinicaltrials.gov
Start Date
March 2011
End Date
December 2013
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

i_gruenwald

MD

Rambam Health Care Campus

Eligibility Criteria

Inclusion Criteria

  • ED of more than 6 months
  • At least 50% unsuccessful to attempt sexual intercourse for 4 times at 4 different days
  • Positive response to PDE-5 inhibitors
  • IIEF-5 domain score of 12-20 denoting mild to severe ED
  • Non-Neurological pathology
  • Stable heterosexual relationship for more than 3 months

Exclusion Criteria

  • NPT - normal/flat
  • Prior prostatectomy surgery
  • Any cause of ED other than vascular related
  • Any unstable medical, psychiatric, spinal cord injury, penile anatomical abnormalities
  • Clinically significant chronic hematological disease
  • Cardiovascular conditions that prevent sexual activity
  • History of heart attack, stroke or life-threatening arrhythmia within the prior 6 months.
  • Cancer within the past 5 years.
  • Anti-androgens, oral or injectable androgens
  • Use of any treatment for ED within 7 days of screening including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories

Outcomes

Primary Outcomes

Change in IIEF-ED Domain Questionaire Score > 5 points is considered treatment success

Time Frame: 13 weeks

Secondary Outcomes

  • Rigidity Score Questionaire- an increase by at least 1 point is considered success(13 weeks)

Study Sites (1)

Loading locations...

Similar Trials